menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Revolutionary Approaches to Improving Outcomes in Unresected LA SCCHN

Are you and your team incorporating the latest data on unresected locally advanced squamous cell carcinoma of the head and neck into practice?

Live Broadcast
1.00 available credits
Information
October 9, 2023
12:00 PM - 01:00 PM EDT
Online
ReachMD Healthcare Image
Details
Presenters
Related
Comments
  • Overview

    Join our international multidisciplinary panel of experts in exploring revolutionary approaches to treating patients with unresectable locally advanced squamous cell carcinoma of the head and neck. Through engaging presentations and discussions, the panel will address key aspects of patient management including new and emerging therapies, the clinical significance of early endpoints used in clinical trials, and future directions in treatment. This is a rebroadcast of the live meeting taking place during ASTRO 2023 in San Diego on October 2, 2023. To participate virtually in the live meeting please click here.

  • Program Schedule

    12:00pm – 12:03:pm   Welcome and Introductions
    12:03pm – 12:07pm    Overview of LA SCCHN 
    12:07pm – 12:17pm    Current Landscape in LA SCCHN
    12:17pm – 12:29pm    Raising Awareness of Emerging Evidence in LA SCCHN
    12:29pm – 12:41pm    A Comprehensive Analysis of IAPs
    12:41pm – 12:50pm    Understanding Clinical Trials and Their Endpoints in LA SCCHN
    12:50pm – 1:00pm      Question and Answer Session (pre-recorded from the Live Meeting) 

     

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Ezra Cohen, MD, FRCPSC, FASCO
    Chief Medical Officer, Oncology
    Tempus Labs
    Professor of Medicine, Division of Hematology/Oncology
    University of California San Diego Health
    San Diego, CA, US

    Consulting Fees: Adagene, Astellas, Cidara, Eisai, Genmab, Gilboa, iTeos, Lilly, MSD, Merck, Nectin Tx, Novartis, Nykode, Pangea Therapeutics, PCI Biotech, Replimune, Roche, Soteria, Tempus, Viracta
    Employee of an ineligible company: Tempus Labs
    Ownership Interest: Kinnate Biopharma, Primmune Therapeutics
    Research: NCI

    Faculty:
    Kevin J Harrington, PhD, FRCP, FRCR, FRSB
    Professor in Biological Cancer Therapies
    The Institute of Cancer Research
    London UK

    Consulting Fees: AstraZeneca, Boehringer Ingelheim, Merck, MSD, Replimune
    Research: AstraZeneca, Boehringer Ingelheim, Replimune

    Deborah J. Wong, MD, PhD
    Associate Clinical Professor of Medicine
    David Geffen School of Medicine
    University of California, Los Angeles
    Los Angeles, CA, US

    Consulting Fees: MSD
    Research: AstraZeneca, BICARA Therapeutics, Bristol-Myers Squibb Company, FSTAR Therapeutics, Genentech, Gilead, KURA Oncology, Lilly, MSD, Pfizer, Regeneron, TopAlliance

    Reviwers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Ann Early has nothing to disclose
    • Robert Giest, MD, has nothing to disclose.
    • Andrea Mathis has nothing to disclose.
    • Tim Person has nothing to disclose.
    • Rosanne Strauss, PharmD, MBA, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Identify the various factors that contribute to the recurrence or progression of locally advanced squamous cell carcinoma of the head and neck (SCCHN)
    • Evaluate the risks, benefits, and limitations of currently available treatment options for managing patients with locally advanced SCCHN, and develop a comprehensive management plan based on patient-specific factors
    • Discuss the mechanisms of action of agents currently under investigation for the treatment of locally advanced SCCHN alongside those of currently available treatment options, and potential implications for patient care
    • Assess the therapeutic potential and potential impact on current treatment paradigms of emerging agents being investigated for the management of locally advanced SCCHN
    • Compare the definitions, benefits, and limitations of early endpoints used in oncology trials and their relation to patient outcomes
    • Describe the evidence, rationale, and clinical significance of early endpoints used in ongoing clinical trials in locally advanced SCCHN
  • Target Audience

    This activity is designed to meet the educational needs of medical oncologists, radiation oncologists, pathologists, and other healthcare professional treating patients with head and neck cancers in the United States.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

  • Commercial Support

    This activity is supported by an independent educational grant from EMD Serono, Inc. EMD Serono, Inc. is the Healthcare business of Merck KGaA, Darmstadt, Germany.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

Facebook Comments

Details
Presenters
Related
Comments
Recommended
  • Overview

    Join our international multidisciplinary panel of experts in exploring revolutionary approaches to treating patients with unresectable locally advanced squamous cell carcinoma of the head and neck. Through engaging presentations and discussions, the panel will address key aspects of patient management including new and emerging therapies, the clinical significance of early endpoints used in clinical trials, and future directions in treatment. This is a rebroadcast of the live meeting taking place during ASTRO 2023 in San Diego on October 2, 2023. To participate virtually in the live meeting please click here.

  • Program Schedule

    12:00pm – 12:03:pm   Welcome and Introductions
    12:03pm – 12:07pm    Overview of LA SCCHN 
    12:07pm – 12:17pm    Current Landscape in LA SCCHN
    12:17pm – 12:29pm    Raising Awareness of Emerging Evidence in LA SCCHN
    12:29pm – 12:41pm    A Comprehensive Analysis of IAPs
    12:41pm – 12:50pm    Understanding Clinical Trials and Their Endpoints in LA SCCHN
    12:50pm – 1:00pm      Question and Answer Session (pre-recorded from the Live Meeting) 

     

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Ezra Cohen, MD, FRCPSC, FASCO
    Chief Medical Officer, Oncology
    Tempus Labs
    Professor of Medicine, Division of Hematology/Oncology
    University of California San Diego Health
    San Diego, CA, US

    Consulting Fees: Adagene, Astellas, Cidara, Eisai, Genmab, Gilboa, iTeos, Lilly, MSD, Merck, Nectin Tx, Novartis, Nykode, Pangea Therapeutics, PCI Biotech, Replimune, Roche, Soteria, Tempus, Viracta
    Employee of an ineligible company: Tempus Labs
    Ownership Interest: Kinnate Biopharma, Primmune Therapeutics
    Research: NCI

    Faculty:
    Kevin J Harrington, PhD, FRCP, FRCR, FRSB
    Professor in Biological Cancer Therapies
    The Institute of Cancer Research
    London UK

    Consulting Fees: AstraZeneca, Boehringer Ingelheim, Merck, MSD, Replimune
    Research: AstraZeneca, Boehringer Ingelheim, Replimune

    Deborah J. Wong, MD, PhD
    Associate Clinical Professor of Medicine
    David Geffen School of Medicine
    University of California, Los Angeles
    Los Angeles, CA, US

    Consulting Fees: MSD
    Research: AstraZeneca, BICARA Therapeutics, Bristol-Myers Squibb Company, FSTAR Therapeutics, Genentech, Gilead, KURA Oncology, Lilly, MSD, Pfizer, Regeneron, TopAlliance

    Reviwers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Ann Early has nothing to disclose
    • Robert Giest, MD, has nothing to disclose.
    • Andrea Mathis has nothing to disclose.
    • Tim Person has nothing to disclose.
    • Rosanne Strauss, PharmD, MBA, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Identify the various factors that contribute to the recurrence or progression of locally advanced squamous cell carcinoma of the head and neck (SCCHN)
    • Evaluate the risks, benefits, and limitations of currently available treatment options for managing patients with locally advanced SCCHN, and develop a comprehensive management plan based on patient-specific factors
    • Discuss the mechanisms of action of agents currently under investigation for the treatment of locally advanced SCCHN alongside those of currently available treatment options, and potential implications for patient care
    • Assess the therapeutic potential and potential impact on current treatment paradigms of emerging agents being investigated for the management of locally advanced SCCHN
    • Compare the definitions, benefits, and limitations of early endpoints used in oncology trials and their relation to patient outcomes
    • Describe the evidence, rationale, and clinical significance of early endpoints used in ongoing clinical trials in locally advanced SCCHN
  • Target Audience

    This activity is designed to meet the educational needs of medical oncologists, radiation oncologists, pathologists, and other healthcare professional treating patients with head and neck cancers in the United States.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

  • Commercial Support

    This activity is supported by an independent educational grant from EMD Serono, Inc. EMD Serono, Inc. is the Healthcare business of Merck KGaA, Darmstadt, Germany.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

Facebook Comments

Schedule25 Jun 2024